Intelligence · Drug directory
Withdrawn Drug Applications
Drugs with withdrawn or discontinued regulatory applications in the US or EU — useful for competitive and label-history research.
Quick answer
Withdrawn applications: NovaPharmaNews tracks 229 pharmaceutical drugs in this segment. Drugs with withdrawn or discontinued regulatory applications in the US or EU — useful for competitive and label-history research.
-
pridopidine
NURZIGMA
N07 -
recombinant salmon calcitonin
FORCALTONIN
H05BA01 -
regdanvimab
REGKIRONA
J06BD06 -
reteplase
ECOKINASE
B01AD07 -
retigabine
TROBALT
N03AX21 -
rimonabant
ZIMULTI
A08AX01 -
rolapitant
VARUBY
A04AD -
rotavirus vaccine
ROTASHIELD
J07BH -
rubitecan
ORATHECIN
-
ruboxistaurin
ARXXANT
-
sasanlimab
ZUMRAD
L01FF -
satavaptan
AQUILDA
-
satraplatin
ORPLATNA
-
semuloparin sodium
MULSEVO
-
shingles (herpes zoster) vaccine (live)
ZOSTAVAX
J07BK02 -
simeprevir
OLYSIO
J05AE14 -
sinapultide
SURFAXIN
-
sirukumab
PLIVENSIA
L04AC -
sitaxentan sodium
THELIN
C02KX03 -
solithromycin
SOLITHROMYCIN TRISKEL EU SERVICES
J01FA -
sotrovimab
XEVUDY
J06BD05 -
strontium ranelate
OSSEOR
M05BX03 -
sulesomab
LEUKOSCAN
VO4D -
surufatinib
SEVSURY
L01EX01
Frequently asked questions
How many withdrawn drugs are listed?
229 drug profiles match this regulatory segment in our published index.
Where does approval data come from?
Profiles combine FDA Drugs@FDA, EMA EPAR references, and regional authority feeds. See our data sources page for attribution.